0
Research Papers

Monitoring neoadjuvant chemotherapy in breast cancer using quantitative diffuse optical spectroscopy: a case study

[+] Author Affiliations
Dorota B. Jakubowski, Albert E. Cerussi, Fre´de´ric Bevilacqua, Natasha Shah

University of California, Irvine, Beckman Laser Institute, Laser Microbeam and Medical Program, 1002 Health Sciences Road East, Irvine, California?92612

David Hsiang, John Butler

University of California, Irvine Medical Center, Chao Family Comprehensive Cancer Center, 101 The City Drive South, Orange, California?92868

Bruce J. Tromberg

University of California, Irvine, Beckman Laser Institute, Laser Microbeam and Medical Program 1002 Health Sciences Road East, Irvine, California?92612E-mail: bjtrombe@uci.edu

J. Biomed. Opt. 9(1), 230-238 (Jan 01, 2004). doi:10.1117/1.1629681
History: Received Feb. 10, 2003; Revised Jun. 27, 2003; Accepted Jul. 1, 2003; Online January 07, 2004
Text Size: A A A

Presurgical chemotherapy is widely used in the treatment of locally advanced breast cancer. Monitoring the response to therapy can improve survival and reduce morbidity. We employ a noninvasive, near-infrared method based on diffuse optical spectroscopy (DOS) to quantitatively monitor tumor response to neoadjuvant chemotherapy. DOS was used to monitor tumor response in one patient with locally advanced breast cancer throughout the course of her therapy. Measurements were performed prior to doxorubicin-cyclophosphamide therapy and at several time points over the course of three treatment cycles (68 days). Our results show strong tumor to normal (T/N) tissue contrast in total hemoglobin concentration (T/N=2.4), water fraction (T/N=6.9), tissue hemoglobin oxygen saturation, StO2 (T/N=0.9), and lipid fraction (T/N=0.7) prior to treatment. Over a 10-week period, the peak total hemoglobin and water dropped 56 and 67%, respectively. Lipid content nearly returned to baseline (T/N =0.9) while StO2 exceeded pretreatment levels (T/N =1.5). Approximately half of the hemoglobin and water changes occurred within 5 days of treatment (26 and 37%, respectively). These data suggest that noninvasive, quantitative optical methods that characterize tumor physiology may be useful in assessing and optimizing individual response to neoadjuvant chemotherapy. © 2004 Society of Photo-Optical Instrumentation Engineers.

Figures in this Article
© 2004 Society of Photo-Optical Instrumentation Engineers

Citation

Dorota B. Jakubowski ; David Hsiang ; Bruce J. Tromberg ; John Butler ; Albert E. Cerussi, et al.
"Monitoring neoadjuvant chemotherapy in breast cancer using quantitative diffuse optical spectroscopy: a case study", J. Biomed. Opt. 9(1), 230-238 (Jan 01, 2004). ; http://dx.doi.org/10.1117/1.1629681


Access This Article
Sign In to Access Full Content
Please Wait... Processing your request... Please Wait.
Sign in or Create a personal account to Buy this article ($20 for members, $25 for non-members).
 
Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Related Book Chapters

Topic Collections

PubMed Articles
Advertisement

Buy this article ($18 for members, $25 for non-members).
Sign In